1
|
Wang DD, Zhang R, Tang LY, Long GQ, Yan H, Yang YC, Guo ZF, Zheng YY, Wang Y, Jia JM, Wang AH. (±)-Salvicatone A: A Pair of C 27-Meroterpenoid Enantiomers with Skeletons from the Roots and Rhizomes of Salvia castanea Diels f. tomentosa Stib. J Org Chem 2024; 89:12894-12901. [PMID: 37976373 DOI: 10.1021/acs.joc.3c01664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2023]
Abstract
(±)-Salvicatone A (1), a C27-meroterpenoid featuring a unique 6/6/6/6/6-pentacyclic carbon skeleton with a 7,8,8a,9,10,10a-hexahydropyren-1 (6H)-one motif, was isolated from the roots and rhizomes of Salvia castanea Diels f. tomentosa Stib. Its structure was characterized by comprehensive spectroscopic analyses along with computer-assisted structure elucidation, including ACD/structure elucidator and quantum chemical calculations with 1H/13C NMR and electronic circular dichroism. Biogenetically, compound 1 was constructed from decarboxylation following [4 + 2] Diels-Alder cycloaddition reaction between caffeic acid and miltirone analogue. Bioassays showed that (-)-1 and (+)-1 inhibited nitric oxide production in lipopolysaccharide-induced RAW264.7 macrophage cells with an IC50 value of 6.48 ± 1.25 and 15.76 ± 5.55 μM, respectively. The structure-based virtual screening based on the pharmacophores in ePharmaLib, as well as the molecular docking and molecular dynamics simulations study, implied that (-)-1 and (+)-1 may potentially bind to retinoic acid receptor-related orphan receptor C to exert anti-inflammatory activities.
Collapse
Affiliation(s)
- Dong-Dong Wang
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China
| | - Rui Zhang
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China
| | - Lian-Yu Tang
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China
| | - Guo-Qing Long
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China
| | - Hui Yan
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China
| | - Yong-Cheng Yang
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China
| | - Zi-Feng Guo
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China
| | - Ying-Ying Zheng
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China
| | - Yong Wang
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China
| | - Jing-Ming Jia
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China
| | - An-Hua Wang
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China
| |
Collapse
|
2
|
Rao C, Zhang T, Huang H. Dialkylation of CF 2 unit enabled by cobalt electron-shuttle catalysis. Nat Commun 2024; 15:7924. [PMID: 39256384 PMCID: PMC11387730 DOI: 10.1038/s41467-024-51532-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2024] [Accepted: 08/07/2024] [Indexed: 09/12/2024] Open
Abstract
The incorporation of difluoromethylene (CF2) group into chemical molecules often imparts desirable properties such as lipophilicity, binding affinity, and thermal stability. Consequently, the increasing demand for gem-difluoroalkylated compounds in drug discovery and materials science has continued to drive the development of practical methods for their synthesis. However, traditional synthetic methods such as deoxofluorination often confront challenges including complicated substrate synthesis sequences and poor functional group compatibility. In this context, we herein report a metal electron-shuttle catalyzed, modular synthetic methodology for difluoroalkylated compounds by assembling two C(sp3) fragments across CF2 unit in a single step. The approach harnesses a difluoromethylene synthon as a biradical linchpin, achieving the construction of two C(sp3)-CF2 bonds through radical addition to two different π-unsaturated molecules. This catalytic protocol is compatible with broad range of coupling partners including diverse olefins, iminiums, and hydrazones, supporting endeavors in the efficient construction of C(sp3)-rich difluoroalkylated molecules.
Collapse
Affiliation(s)
- Changqing Rao
- Key Laboratory of Precision and Intelligent Chemistry, and Department of Chemistry, University of Science and Technology of China, Hefei, 230026, P. R. China
| | - Tianze Zhang
- Key Laboratory of Precision and Intelligent Chemistry, and Department of Chemistry, University of Science and Technology of China, Hefei, 230026, P. R. China
| | - Hanmin Huang
- Key Laboratory of Precision and Intelligent Chemistry, and Department of Chemistry, University of Science and Technology of China, Hefei, 230026, P. R. China.
| |
Collapse
|
3
|
Neal WM, Pandey P, Khan SI, Khan IA, Chittiboyina AG. Machine learning and traditional QSAR modeling methods: a case study of known PXR activators. J Biomol Struct Dyn 2024; 42:903-917. [PMID: 37059719 DOI: 10.1080/07391102.2023.2196701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2022] [Accepted: 03/22/2023] [Indexed: 04/16/2023]
Abstract
Pregnane X receptor (PXR), extensively expressed in human tissues related to digestion and metabolism, is responsible for recognizing and detoxifying diverse xenobiotics encountered by humans. To comprehend the promiscuous nature of PXR and its ability to bind a variety of ligands, computational approaches, viz., quantitative structure-activity relationship (QSAR) models, aid in the rapid dereplication of potential toxicological agents and mitigate the number of animals used to establish a meaningful regulatory decision. Recent advancements in machine learning techniques accommodating larger datasets are expected to aid in developing effective predictive models for complex mixtures (viz., dietary supplements) before undertaking in-depth experiments. Five hundred structurally diverse PXR ligands were used to develop traditional two-dimensional (2D) QSAR, machine-learning-based 2D-QSAR, field-based three-dimensional (3D) QSAR, and machine-learning-based 3D-QSAR models to establish the utility of predictive machine learning methods. Additionally, the applicability domain of the agonists was established to ensure the generation of robust QSAR models. A prediction set of dietary PXR agonists was used to externally-validate generated QSAR models. QSAR data analysis revealed that machine-learning 3D-QSAR techniques were more accurate in predicting the activity of external terpenes with an external validation squared correlation coefficient (R2) of 0.70 versus an R2 of 0.52 in machine-learning 2D-QSAR. Additionally, a visual summary of the binding pocket of PXR was assembled from the field 3D-QSAR models. By developing multiple QSAR models in this study, a robust groundwork for assessing PXR agonism from various chemical backbones has been established in anticipation of the identification of potential causative agents in complex mixtures.
Collapse
Affiliation(s)
- William M Neal
- Division of Pharmacognosy, Department of BioMolecular Sciences, School of Pharmacy, The University of Mississippi, University, MS, USA
| | - Pankaj Pandey
- National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS, USA
| | - Shabana I Khan
- Division of Pharmacognosy, Department of BioMolecular Sciences, School of Pharmacy, The University of Mississippi, University, MS, USA
- National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS, USA
| | - Ikhlas A Khan
- Division of Pharmacognosy, Department of BioMolecular Sciences, School of Pharmacy, The University of Mississippi, University, MS, USA
- National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS, USA
| | - Amar G Chittiboyina
- National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, University, MS, USA
| |
Collapse
|
4
|
Huber AD, Poudel S, Li Y, Lin W, Wu J, Miller DJ, Chen T. Ligand flexibility and binding pocket malleability cooperate to allow selective PXR activation by analogs of a promiscuous nuclear receptor ligand. Structure 2023; 31:1545-1555.e9. [PMID: 37729916 PMCID: PMC10872772 DOI: 10.1016/j.str.2023.08.020] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Revised: 08/01/2023] [Accepted: 08/23/2023] [Indexed: 09/22/2023]
Abstract
The human nuclear receptor (NR) family of transcription factors contains 48 proteins that bind lipophilic molecules. Approved NR therapies have had immense success treating various diseases, but lack of selectivity has hindered efforts to therapeutically target the majority of NRs due to unpredictable off-target effects. The synthetic ligand T0901317 was originally discovered as a potent agonist of liver X receptors (LXRα/β) but subsequently found to target additional NRs, with activation of pregnane X receptor (PXR) being as potent as that of LXRs. We previously showed that directed rigidity reduces PXR binding by T0901317 derivatives through unfavorable protein remodeling. Here, we use a similar approach to achieve selectivity for PXR over other T0901317-targeted NRs. One molecule, SJPYT-318, accomplishes selectivity by favorably utilizing PXR's flexible binding pocket and surprisingly binding in a new mode distinct from the parental T0901317. Our work provides a structure-guided framework to achieve NR selectivity from promiscuous compounds.
Collapse
Affiliation(s)
- Andrew D Huber
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
| | - Shyaron Poudel
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
| | - Yongtao Li
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
| | - Wenwei Lin
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
| | - Jing Wu
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
| | - Darcie J Miller
- Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
| | - Taosheng Chen
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
| |
Collapse
|
5
|
Fouda A, Negi S, Zaremba O, Gaidar RS, Moroz YS, Rusanov E, Paraskevas S, Tchervenkov J. Discovery, Synthesis, and In Vitro Characterization of 2,3 Derivatives of 4,5,6,7-Tetrahydro-Benzothiophene as Potent Modulators of Retinoic Acid Receptor-Related Orphan Receptor γt. J Med Chem 2023; 66:7355-7373. [PMID: 37172324 PMCID: PMC10259452 DOI: 10.1021/acs.jmedchem.3c00021] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Indexed: 05/14/2023]
Abstract
Retinoic acid receptor-related orphan receptor γt (RORγt) is a nuclear receptor that is expressed in a variety of tissues and is a potential drug target for the treatment of inflammatory and auto-immune diseases, metabolic diseases, and resistant cancer types. We herein report the discovery of 2,3 derivatives of 4,5,6,7-tetrahydro-benzothiophene modulators of RORγt. We also report the solubility in acidic/neutral pH, mouse/human/dog/rat microsomal stability, Caco-2, and MDR1-MDCKII permeabilities of a set of these derivatives. For this group of modulators, inverse agonism by steric clashes and push-pull mechanisms induce greater instability to protein conformation compared to agonist lock hydration. Independent of the two mechanisms, we observed a basal modulatory activity of the tested 2,3 derivatives of 4,5,6,7-tetrahydro-benzothiophene toward RORγt due to the interactions with the Cys320-Glu326 and Arg364-Phe377 hydrophilic regions. The drug discovery approach reported in the current study can be employed to discover modulators of nuclear receptors and other globular protein targets.
Collapse
Affiliation(s)
- Ahmed Fouda
- Department
of Experimental Surgery, McGill University, Montréal, Québec H3G 1A4, Canada
- Research
Institute of the McGill University Health Centre, Montréal, Québec H3H 2R9, Canada
| | - Sarita Negi
- Research
Institute of the McGill University Health Centre, Montréal, Québec H3H 2R9, Canada
| | | | | | - Yurii S. Moroz
- Chemspace
LLC, Kyïv 02094, Ukraine
- Taras
Shevchenko National University of Kyïv, Kyïv 01601, Ukraine
| | - Eduard Rusanov
- Institute
of Organic Chemistry, National Academy of
Sciences of Ukraine, Kyïv 02094, Ukraine
- Department
of Chemistry and Applied Biosciences, ETH
Zürich, Zürich CH-8093, Switzerland
| | - Steven Paraskevas
- Department
of Experimental Surgery, McGill University, Montréal, Québec H3G 1A4, Canada
- Research
Institute of the McGill University Health Centre, Montréal, Québec H3H 2R9, Canada
- Department
of Surgery, McGill University, Montréal, Québec H3G 1A4, Canada
- McGill
University Health Centre, Montréal, Québec H4A 3J1, Canada
| | - Jean Tchervenkov
- Department
of Experimental Surgery, McGill University, Montréal, Québec H3G 1A4, Canada
- Research
Institute of the McGill University Health Centre, Montréal, Québec H3H 2R9, Canada
- Department
of Surgery, McGill University, Montréal, Québec H3G 1A4, Canada
- McGill
University Health Centre, Montréal, Québec H4A 3J1, Canada
| |
Collapse
|
6
|
Zhang J, Chen B, Zhang C, Sun N, Huang X, Wang W, Fu W. Modes of action insights from the crystallographic structures of retinoic acid receptor-related orphan receptor-γt (RORγt). Eur J Med Chem 2023; 247:115039. [PMID: 36566711 DOI: 10.1016/j.ejmech.2022.115039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Revised: 11/29/2022] [Accepted: 12/19/2022] [Indexed: 12/24/2022]
Abstract
RORγt plays an important role in mediating IL-17 production and some tumor cells. It has four functional domains, of which the ligand-binding domain (LBD) is responsible for binding agonists to recruit co-activators or inverse agonists to prevent co-activator recruiting the agonists. Thus, potent ligands targeting the LBD of this protein could provide novel treatments for cancer and autoimmune diseases. In this perspective, we summarized and discussed various modes of action (MOA) of RORγt-ligand binding structures. The ligands can bind with RORγt at either orthosteric site or the allosteric site, and the binding modes at these two sites are different for agonists and inverse agonist. At the orthosteric site, the binding of agonist is to stabilize the H479-Y502-F506 triplet interaction network of RORγt. The binding of inverse agonist features as these four apparent ways: (1) blocking the entrance of the agonist pocket in RORγt; (2) directly breaking the H479-Y502 pair interactions; (3) destabilizing the triplet H479-Y502-F506 interaction network through perturbing the conformation of the side chain in M358 at the bottom of the binding pocket; (4) and destabilizing the triplet H479-Y502-F506 through changing the conformation of the side chain of residue W317 side chain. At the allosteric site of RORγt, the binding of inverse agonist was found recently to inhibit the activation of protein by interacting directly with H12, which results in unfolding of helix 11' and orientation of H12 to directly block cofactor peptide binding. This overview of recent advances in the RORγt structures is expected to provide a guidance of designing more potent drugs to treat RORγt-related diseases.
Collapse
Affiliation(s)
- Junjie Zhang
- School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China
| | - Baiyu Chen
- School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China
| | - Chao Zhang
- School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China
| | - Nannan Sun
- School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China
| | - Xiaoqin Huang
- Center for Research Computing, Office of Information Technology, Center for Theoretical Biological Physics, Rice University, Houston, TX, 77030, USA
| | - Wuqing Wang
- School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China
| | - Wei Fu
- School of Pharmacy & Minhang Hospital, Fudan University, Shanghai, 201301, PR China.
| |
Collapse
|
7
|
Pham B, Cheng Z, Lopez D, Lindsay RJ, Foutch D, Majors RT, Shen T. Statistical Analysis of Protein-Ligand Interaction Patterns in Nuclear Receptor RORγ. Front Mol Biosci 2022; 9:904445. [PMID: 35782874 PMCID: PMC9240913 DOI: 10.3389/fmolb.2022.904445] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Accepted: 05/16/2022] [Indexed: 11/21/2022] Open
Abstract
The receptor RORγ belongs to the nuclear receptor superfamily that senses small signaling molecules and regulates at the gene transcription level. Since RORγ has a high basal activity and plays an important role in immune responses, inhibitors targeting this receptor have been a focus for many studies. The receptor-ligand interaction is complex, and often subtle differences in ligand structure can determine its role as an inverse agonist or an agonist. We examined more than 130 existing RORγ crystal structures that have the same receptor complexed with different ligands. We reported the features of receptor-ligand interaction patterns and the differences between agonist and inverse agonist binding. Specific changes in the contact interaction map are identified to distinguish active and inactive conformations. Further statistical analysis of the contact interaction patterns using principal component analysis reveals a dominant mode which separates allosteric binding vs. canonical binding and a second mode which may indicate active vs. inactive structures. We also studied the nature of constitutive activity by performing a 100-ns computer simulation of apo RORγ. Using constitutively active nuclear receptor CAR as a comparison, we identified a group of conserved contacts that have similar contact strength between the two receptors. These conserved contact interactions, especially a couple key contacts in H11–H12 interaction, can be considered essential to the constitutive activity of RORγ. These protein-ligand and internal protein contact interactions can be useful in the development of new drugs that direct receptor activity.
Collapse
Affiliation(s)
- Bill Pham
- Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, United States
| | - Ziju Cheng
- Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, United States
| | - Daniel Lopez
- Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, United States
| | - Richard J. Lindsay
- UT-ORNL Graduate School of Genome Science and Technology, Knoxville, TN, United States
| | - David Foutch
- UT-ORNL Graduate School of Genome Science and Technology, Knoxville, TN, United States
| | - Rily T. Majors
- Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, United States
| | - Tongye Shen
- Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, TN, United States
- *Correspondence: Tongye Shen,
| |
Collapse
|
8
|
Suri C, Awasthi A, Asthana S. Crystallographic landscape provides molecular insights into the modes of action of diverse ROR-γt modulators. Drug Discov Today 2021; 27:652-663. [PMID: 34838728 DOI: 10.1016/j.drudis.2021.11.022] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Revised: 08/13/2021] [Accepted: 11/19/2021] [Indexed: 12/24/2022]
Abstract
ROR-γt, the master regulator of Th-17 cells, is activated by the binding of small molecules at its orthosteric site, followed by the recruitment of co-activators or co-repressors in the ligand binding domain (LBD). Th-17 cells provide immune-dependent protection against cancers and pathogens. Their dysregulation causes inflammation and is therefore implicated in various autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and psoriasis. Consequently, there is enormous interest in the development of ROR-γt modulators, both agonist and inverse-agonists. Here, we review advances in the development of ROR-γt modulators that have been made over the past decade, focusing on the rich crystallography landscape for ROR-γt co-crystals that has delineated the relationship between the binding patterns of modulators and the resulting biological activities.
Collapse
Affiliation(s)
- Charu Suri
- Translational Health Science and Technology Institute (THSTI), Haryana 121001, India.
| | - Amit Awasthi
- Translational Health Science and Technology Institute (THSTI), Haryana 121001, India.
| | - Shailendra Asthana
- Translational Health Science and Technology Institute (THSTI), Haryana 121001, India.
| |
Collapse
|
9
|
Li Z, Liu T, He X, Bai C. The evolution paths of some reprehensive scaffolds of RORγt modulators, a perspective from medicinal chemistry. Eur J Med Chem 2021; 228:113962. [PMID: 34776280 DOI: 10.1016/j.ejmech.2021.113962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 10/19/2021] [Accepted: 10/27/2021] [Indexed: 11/29/2022]
Abstract
The ligand binding domain (LBD) of retinoid-related orphan nuclear receptor γt (RORγt) has been exploited as a promising target for the new small molecule therapeutics to cure autoimmune diseases via modulating the IL-17 and IL-22 production by Th17 cells. Diverse chemical scaffolds of these small molecules have been discovered by multiple groups with methods such as high throughput screening (HTS) and virtual screening. These different scaffolds are further developed by medicinal chemists to afford lead compounds the best of which enter clinical trials. In this review, we summarize these chemical scaffolds and their evolution paths according to the groups in which they have been discovered or studied. We combine the data of the chemistry, biological assays and structural biology of each chemical scaffold, in order to afford insight to develop new RORγt modulators with higher potency, less toxicity and elucidated working mechanism.
Collapse
Affiliation(s)
- Zhuohao Li
- Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China; Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China
| | - Tao Liu
- Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China; Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China
| | - Xixin He
- School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
| | - Chuan Bai
- Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China; Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.
| |
Collapse
|
10
|
Zou H, Yang N, Zhang X, Chen HW. RORγ is a context-specific master regulator of cholesterol biosynthesis and an emerging therapeutic target in cancer and autoimmune diseases. Biochem Pharmacol 2021; 196:114725. [PMID: 34384758 DOI: 10.1016/j.bcp.2021.114725] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 08/04/2021] [Accepted: 08/05/2021] [Indexed: 01/04/2023]
Abstract
Aberrant cholesterol metabolism and homeostasis in the form of elevated cholesterol biosynthesis and dysregulated efflux and metabolism is well recognized as a major feature of metabolic reprogramming in solid tumors. Recent studies have emphasized on major drivers and regulators such as Myc, mutant p53, SREBP2, LXRs and oncogenic signaling pathways that play crucial roles in tumor cholesterol metabolic reprogramming. Therapeutics such as statins targeting the mevalonate pathway were tried at the clinic without showing consistent benefits to cancer patients. Nuclear receptors are prominent regulators of mammalian metabolism. Their de-regulation often drives tumorigenesis. RORγ and its immune cell-specific isoform RORγt play important functions in control of mammalian metabolism, circadian rhythm and immune responses. Although RORγ, together with its closely related members RORα and RORβ were identified initially as orphan receptors, recent studies strongly support the conclusion that specific intermediates and metabolites of cholesterol pathways serve as endogenous ligands of RORγ. More recent studies also reveal a critical role of RORγ in tumorigenesis through major oncogenic pathways including acting a new master-like regulator of tumor cholesterol biosynthesis program. Importantly, an increasing number of RORγ orthosteric and allosteric ligands are being identified that display potent activities in blocking tumor growth and autoimmune disorders in preclinical models. This review summarizes the recent preclinical and clinical progress on RORγ with emphasis on its role in reprogramming tumor cholesterol metabolism and its regulation. It will also discuss RORγ functional mechanisms, context-specificity and its value as a therapeutic target for effective cancer treatment.
Collapse
Affiliation(s)
- Hongye Zou
- Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, California, USA
| | - Nianxin Yang
- Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, California, USA
| | - Xiong Zhang
- Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, California, USA
| | - Hong-Wu Chen
- Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, California, USA; UC Davis Comprehensive Cancer Center, University of California, Davis, Sacramento, California, USA; VA Northern California Health Care System, Mather, California, USA.
| |
Collapse
|
11
|
Dong X, Yuan X, Song Z, Wang Q. The development of an Amber-compatible organosilane force field for drug-like small molecules. Phys Chem Chem Phys 2021; 23:12582-12591. [PMID: 34037028 DOI: 10.1039/d1cp01169c] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
As members of the group IVA elements, silicon and carbon have long been thought of as isosteres of each other in drug design. However, the lack of silicon parameters in current main stream force fields hinders the computational study of this important element in drug discovery. Thus, in this study, we attempted to supplement the parameters of organosilanes in the General Amber Force Field (GAFF2). The parameters have been designed following the principles of GAFF2 to make it compatible with the Amber force field family. The accuracy of the parameters was discussed by comparing the pair interaction energy, the liquid properties, and the structures and alchemical binding free energy differences for a set of protein-ligand complexes.
Collapse
Affiliation(s)
- Xue Dong
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, P. R. China.
| | - Xinghang Yuan
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, P. R. China.
| | - Zhenlei Song
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, P. R. China.
| | - Qiantao Wang
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, P. R. China.
| |
Collapse
|
12
|
Hall A, Chanteux H, Ménochet K, Ledecq M, Schulze MSED. Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches. J Med Chem 2021; 64:6413-6522. [PMID: 34003642 DOI: 10.1021/acs.jmedchem.0c02245] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
This perspective discusses the role of pregnane xenobiotic receptor (PXR) in drug discovery and the impact of its activation on CYP3A4 induction. The use of structural biology to reduce PXR activity on drug discovery projects has become more common in recent years. Analysis of this work highlights several important molecular interactions, and the resultant structural modifications to reduce PXR activity are summarized. The computational approaches undertaken to support the design of new drugs devoid of PXR activation potential are also discussed. Finally, the SAR of empirical design strategies to reduce PXR activity is reviewed, and the key SAR transformations are discussed and summarized. In conclusion, this perspective demonstrates that PXR activity can be greatly diminished or negated on active drug discovery projects with the knowledge now available. This perspective should be useful to anyone who seeks to reduce PXR activity on a drug discovery project.
Collapse
Affiliation(s)
- Adrian Hall
- UCB, Avenue de l'Industrie, Braine-L'Alleud 1420, Belgium
| | | | | | - Marie Ledecq
- UCB, Avenue de l'Industrie, Braine-L'Alleud 1420, Belgium
| | | |
Collapse
|
13
|
Lugar CW, Clarke CA, Morphy R, Rudyk H, Sapmaz S, Stites RE, Vaught GM, Furness K, Broughton HB, Durst GL, Clawson DK, Stout SL, Guo SY, Durbin JD, Stayrook KR, Edmondson DD, Kikly K, New NE, Bina HA, Chambers MG, Shetler P, Chang WY, Chang VCY, Barr R, Gough WH, Steele JP, Getman B, Patel N, Mathes BM, Richardson TI. Defining Target Engagement Required for Efficacy In Vivo at the Retinoic Acid Receptor-Related Orphan Receptor C2 (RORγt). J Med Chem 2021; 64:5470-5484. [PMID: 33852312 DOI: 10.1021/acs.jmedchem.0c01918] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The Th17 pathway has been implicated in autoimmune diseases. The retinoic acid receptor-related orphan receptor C2 (RORγt) is a master regulator of Th17 cells and controls the expression of IL-17A. RORγt is expressed primarily in IL-17A-producing lymphoid cells. Here we describe a virtual screen of the ligand-binding pocket and subsequent screen in a binding assay that identified the 1-benzyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran]-2'-carboxamide scaffold as a starting point for optimization of binding affinity and functional activity guided by structure-based design. Compound 12 demonstrated activity in a mouse PK/PD model and efficacy in an inflammatory arthritis mouse model that were used to define the level and duration of target engagement required for efficacy in vivo. Further optimization to improve ADME and physicochemical properties with guidance from simulations and modeling provided compound 22, which is projected to achieve the level and duration of target engagement required for efficacy in the clinic.
Collapse
Affiliation(s)
- Charles W Lugar
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Christian A Clarke
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Richard Morphy
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Helene Rudyk
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Selma Sapmaz
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Ryan E Stites
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Grant M Vaught
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Kelly Furness
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Howard B Broughton
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Greg L Durst
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - David K Clawson
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Stephanie L Stout
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Sherry Y Guo
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Jim D Durbin
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Keith R Stayrook
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Denise D Edmondson
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Kristy Kikly
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Nicole E New
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Holly A Bina
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Mark G Chambers
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Pamela Shetler
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - William Y Chang
- Lilly Biotechnology Center, Eli Lilly and Company, San Diego, California 92121, United States
| | - Veavi Ching-Yun Chang
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Rob Barr
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Wendy H Gough
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Jimmy P Steele
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Brian Getman
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Nita Patel
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Brian M Mathes
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Timothy I Richardson
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| |
Collapse
|
14
|
Meijer FA, van den Oetelaar MCM, Doveston RG, Sampers ENR, Brunsveld L. Covalent Occlusion of the RORγt Ligand Binding Pocket Allows Unambiguous Targeting of an Allosteric Site. ACS Med Chem Lett 2021; 12:631-639. [PMID: 33854703 PMCID: PMC8040040 DOI: 10.1021/acsmedchemlett.1c00029] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2021] [Accepted: 03/03/2021] [Indexed: 11/30/2022] Open
Abstract
The nuclear receptor RORγt is a key positive regulator in the differentiation and proliferation of T helper 17 (Th17) cells and the production of proinflammatory cytokines like IL-17a. Dysregulation of this pathway can result in the development of various autoimmune diseases, and inhibition of RORγt with small molecules thus holds great potential as a therapeutic strategy. RORγt has a unique allosteric ligand binding site in the ligand binding domain, which is distinct from the canonical, orthosteric binding site. Allosteric modulation of RORγt shows high potential, but the targeted discovery of novel allosteric ligands is highly challenging via currently available methods. Here, we introduce covalent, orthosteric chemical probes for RORγt that occlude the binding of canonical, orthosteric ligands but still allow allosteric ligand binding. Ultimately, these probes could be used to underpin screening approaches for the unambiguous and rapid identification of novel allosteric RORγt ligands.
Collapse
Affiliation(s)
- Femke A. Meijer
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Technische Universiteit Eindhoven, Den Dolech 2, 5612 AZ Eindhoven, The Netherlands
| | - Maxime C. M. van den Oetelaar
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Technische Universiteit Eindhoven, Den Dolech 2, 5612 AZ Eindhoven, The Netherlands
| | - Richard G. Doveston
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Technische Universiteit Eindhoven, Den Dolech 2, 5612 AZ Eindhoven, The Netherlands
- Leicester Institute of Structural and Chemical Biology and School of Chemistry, University of Leicester, University Road, Leicester LE1 7RH, United Kingdom
| | - Ella N. R. Sampers
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Technische Universiteit Eindhoven, Den Dolech 2, 5612 AZ Eindhoven, The Netherlands
| | - Luc Brunsveld
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Technische Universiteit Eindhoven, Den Dolech 2, 5612 AZ Eindhoven, The Netherlands
| |
Collapse
|
15
|
Harcken C, Csengery J, Turner M, Wu L, Liang S, Sibley R, Brunette S, Labadia M, Hoyt K, Wayne A, Wieckowski T, Davis G, Panzenbeck M, Souza D, Kugler S, Terenzio D, Collin D, Smith D, Fryer RM, Tseng YC, Hehn JP, Fletcher K, Hughes RO. Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357. ACS Med Chem Lett 2021; 12:143-154. [PMID: 33488976 DOI: 10.1021/acsmedchemlett.0c00575] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Accepted: 12/11/2020] [Indexed: 12/17/2022] Open
Abstract
The interleukin (IL)-23/T helper (Th)17 axis plays a critical role in autoimmune diseases, and there is an increasing number of biologic therapies that target IL-23 and IL-17. The transcription factor retinoic acid receptor-related orphan nuclear receptor γt (RORγt) is important for the activation and differentiation of Th17 cells and thus is an attractive pharmacologic target for the treatment of Th17-mediated diseases. A novel series of pyrazinone RORγ antagonists was discovered through hybridization of two distinct screening hits and scaffold hopping. The series offers attractive potency and selectivity in combination with favorable druglike properties, such as metabolic stability and aqueous solubility. Lead optimization identified a clinical candidate, compound (S)-11 (BI 730357), for the treatment of autoimmune diseases.
Collapse
Affiliation(s)
- Christian Harcken
- Department of R&D Project Management and Development Strategies, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Johanna Csengery
- Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Michael Turner
- Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Lifen Wu
- Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Shuang Liang
- Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Robert Sibley
- Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Steven Brunette
- Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Mark Labadia
- Department of Immunology and Respiratory Disease Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Kathleen Hoyt
- Department of Immunology and Respiratory Disease Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Anita Wayne
- Department of Immunology and Respiratory Disease Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Thomas Wieckowski
- Department of Immunology and Respiratory Disease Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Gregg Davis
- Department of Immunology and Respiratory Disease Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Mark Panzenbeck
- Department of Immunology and Respiratory Disease Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Donald Souza
- Department of Immunology and Respiratory Disease Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Stanley Kugler
- Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Donna Terenzio
- Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Delphine Collin
- Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Dustin Smith
- Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Ryan M. Fryer
- Department of Cardiometabolic Diseases Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Yin-Chao Tseng
- Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Jörg P. Hehn
- Department of Medicinal Chemistry Germany, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397 Biberach an der Riß, Germany
| | - Kim Fletcher
- Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| | - Robert O. Hughes
- Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States
| |
Collapse
|
16
|
Michelini S, Ricci M, Serrani R, Stuppia L, Beccari T, Veselenyiova D, Kenanoglu S, Barati S, Kurti D, Baglivo M, Basha SH, Krajcovic J, Dundar M, Bertelli M. Possible Role of the RORC Gene in Primary and Secondary Lymphedema: Review of the Literature and Genetic Study of Two Rare Causative Variants. Lymphat Res Biol 2020; 19:129-133. [PMID: 32960152 DOI: 10.1089/lrb.2020.0030] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Background: RAR-related Orphan Receptor C (RORC) is a DNA-binding transcription factor and the key transcription factor responsible for differentiation of T helper 17 cells. The RORC gene plays a role in lymphoid organogenesis, thymopoiesis, and lymph node organogenesis. The aim of our study was to determine the possible role of RORC in the development of lymphatic system malformations by combining data from the scientific literature and next-generation sequencing of RORC in lymphedema patients negative for known causative genes. Methods and Results: We sequenced RORC in 235 lymphedema patients negative for known lymphedema-associated genes. We found two probands carrying nonsense RORC variants. Conclusions: We show that RORC is important for normal function of the lymphatic system and that a rare variant with a possible causative effect may imply predisposition for lymphedema.
Collapse
Affiliation(s)
- Sandro Michelini
- Department of Vascular Rehabilitation, San Giovanni Battista Hospital, Rome, Italy
| | - Maurizio Ricci
- Rehabilitative Medicine, University Hospital, Ospedali Riuniti of Ancona, Torrette, Italy
| | - Roberta Serrani
- Rehabilitative Medicine, University Hospital, Ospedali Riuniti of Ancona, Torrette, Italy
| | - Liborio Stuppia
- Aging and Translational Medicine Research Center (CeSI-MeT), University "G. d'Annunzio," Chieti-Pescara, Italy
| | - Tommaso Beccari
- Department of Pharmaceutical Sciences, University of Perugia, Via Fabretti 48, Perugia, Italy
| | - Dominika Veselenyiova
- Department of Biology, Faculty of Natural Sciences, University of Ss. Cyril and Methodius in Trnava, Trnava, Slovakia
- MAGI Euregio, Bolzano, Italy
| | - Sercan Kenanoglu
- MAGI Euregio, Bolzano, Italy
- Department of Medical Genetics, Erciyes University, Kayseri, Turkey
| | | | - Danjela Kurti
- MAGI Euregio, Bolzano, Italy
- MAGI-Balkan, Tirana, Albania
| | | | | | - Juraj Krajcovic
- Department of Biology, Faculty of Natural Sciences, University of Ss. Cyril and Methodius in Trnava, Trnava, Slovakia
| | - Munis Dundar
- Department of Medical Genetics, Erciyes University, Kayseri, Turkey
| | - Matteo Bertelli
- MAGI Euregio, Bolzano, Italy
- EBTNA-Lab, Rovereto, TN, Italy
- MAGI's Lab, Rovereto, TN, Italy
| |
Collapse
|
17
|
Huang M, Bolin S, Miller H, Ng HL. RORγ Structural Plasticity and Druggability. Int J Mol Sci 2020; 21:ijms21155329. [PMID: 32727079 PMCID: PMC7432406 DOI: 10.3390/ijms21155329] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Revised: 07/08/2020] [Accepted: 07/15/2020] [Indexed: 12/19/2022] Open
Abstract
Retinoic acid receptor-related orphan receptor γ (RORγ) is a transcription factor regulating the expression of the pro-inflammatory cytokine IL-17 in human T helper 17 (Th17) cells. Activating RORγ can induce multiple IL-17-mediated autoimmune diseases but may also be useful for anticancer therapy. Its deep immunological functions make RORɣ an attractive drug target. Over 100 crystal structures have been published describing atomic interactions between RORɣ and agonists and inverse agonists. In this review, we focus on the role of dynamic properties and plasticity of the RORɣ orthosteric and allosteric binding sites by examining structural information from crystal structures and simulated models. We discuss the possible influences of allosteric ligands on the orthosteric binding site. We find that high structural plasticity favors the druggability of RORɣ, especially for allosteric ligands.
Collapse
Affiliation(s)
- Mian Huang
- Department of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS 66506, USA; (M.H.); (H.M.)
| | - Shelby Bolin
- Division of Biology, Kansas State University, Manhattan, KS 66506, USA;
| | - Hannah Miller
- Department of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS 66506, USA; (M.H.); (H.M.)
| | - Ho Leung Ng
- Department of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS 66506, USA; (M.H.); (H.M.)
- Correspondence:
| |
Collapse
|
18
|
Discovery and optimization of new oxadiazole substituted thiazole RORγt inverse agonists through a bioisosteric amide replacement approach. Bioorg Med Chem Lett 2020; 30:127174. [DOI: 10.1016/j.bmcl.2020.127174] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2020] [Revised: 04/03/2020] [Accepted: 04/05/2020] [Indexed: 01/16/2023]
|
19
|
Shaikh NS, Iyer JP, Munot YS, Mukhopadhyay PP, Raje AA, Nagaraj R, Jamdar V, Gavhane R, Lohote M, Sherkar P, Bala M, Petla R, Meru A, Umrani D, Rouduri S, Joshi S, Reddy S, Kandikere V, Bhuniya D, Kulkarni B, Mookhtiar KA. Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions. Bioorg Med Chem Lett 2019; 29:2208-2217. [PMID: 31272795 DOI: 10.1016/j.bmcl.2019.06.044] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2019] [Revised: 06/13/2019] [Accepted: 06/22/2019] [Indexed: 12/30/2022]
Abstract
Targeting nuclear receptor RORγ is recognized to be beneficial in multiple autoimmune disorders. We disclosed new indole analogues as potent RORγ inverse agonists. RO-2 as one of the potent and orally bioavailable compounds was evaluated in various models of autoimmune disorder. It showed potent suppression of downstream markers of RORγt activity in murine and human primary cells, ex vivo PD assay and in multiple animal models of autoimmune diseases. The results indicate the potential of these indole analogues as orally bioavailable small molecule inverse agonists of RORγt, efficacious in various Th17 driven models of autoimmune disorders.
Collapse
Affiliation(s)
- Nadim S Shaikh
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India.
| | - Jitesh P Iyer
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Yogesh S Munot
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Partha P Mukhopadhyay
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Amol A Raje
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Ranganayaki Nagaraj
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Vijay Jamdar
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Ravindra Gavhane
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Mahendra Lohote
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Prasad Sherkar
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Madhu Bala
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Rajkanth Petla
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Ashwinkumar Meru
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Dhananjay Umrani
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Sreekanth Rouduri
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Sachin Joshi
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Satyanarayan Reddy
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Vishwottam Kandikere
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Debnath Bhuniya
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Bheemashankar Kulkarni
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| | - Kasim A Mookhtiar
- Drug Discovery Facility - Pune, Advinus Therapeutics Limited, Head Office: Block No. 21 & 22, Phase II, Peenya Industrial Area, Bangalore 560058, India
| |
Collapse
|
20
|
von Berg S, Xue Y, Collins M, Llinas A, Olsson RI, Halvarsson T, Lindskog M, Malmberg J, Jirholt J, Krutrök N, Ramnegård M, Brännström M, Lundqvist A, Lepistö M, Aagaard A, McPheat J, Hansson EL, Chen R, Xiong Y, Hansson TG, Narjes F. Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2. ACS Med Chem Lett 2019; 10:972-977. [PMID: 31223457 DOI: 10.1021/acsmedchemlett.9b00158] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Accepted: 05/29/2019] [Indexed: 12/31/2022] Open
Abstract
The further optimization of a recently disclosed series of inverse agonists of the nuclear receptor RORC2 is described. Investigations into the left-hand side of compound 1, guided by X-ray crystal structures, led to the substitution of the 4-aryl-thiophenyl residue with the hexafluoro-2-phenyl-propan-2-ol moiety. This change resulted in to compound 28, which combined improved drug-like properties with good cell potency and a significantly lower dose, using an early dose to man prediction. Target engagement in vivo was demonstrated in the thymus of mice by a reduction in the number of double positive T cells after oral dosing.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Rongfeng Chen
- Pharmaron Beijing Co., Ltd., Taihe Road BDA, Beijing 100176, P. R. China
| | - Yao Xiong
- Pharmaron Beijing Co., Ltd., Taihe Road BDA, Beijing 100176, P. R. China
| | | | | |
Collapse
|
21
|
Doebelin C, He Y, Campbell S, Nuhant P, Kumar N, Koenig M, Garcia-Ordonez R, Chang MR, Roush WR, Lin L, Kahn S, Cameron MD, Griffin PR, Solt LA, Kamenecka TM. Discovery and Optimization of a Series of Sulfonamide Inverse Agonists for the Retinoic Acid Receptor-Related Orphan Receptor-α. Med Chem 2019; 15:676-684. [PMID: 30799793 DOI: 10.2174/1573406415666190222124745] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2018] [Revised: 01/04/2019] [Accepted: 02/07/2019] [Indexed: 11/22/2022]
Abstract
BACKGROUND Despite a massive industry endeavor to develop RORγ-modulators for autoimmune disorders, there has been no indication of efforts to target the close family member RORα for similar indications. This may be due to the misconception that RORα is redundant to RORγ, or the inherent difficulty in cultivating tractable starting points for RORα. RORα-selective modulators would be useful tools to interrogate the biology of this understudied orphan nuclear receptor. OBJECTIVE The goal of this research effort was to identify and optimize synthetic ligands for RORα starting from the known LXR agonist T0901317. METHODS Fourty-five analogs of the sulfonamide lead (1) were synthesized and evaluated for their ability to suppress the transcriptional activity of RORα, RORγ, and LXRα in cell-based assays. Analogs were characterized by 1H-NMR, 13C-NMR, and LC-MS analysis. The pharmacokinetic profile of the most selective RORα inverse agonist was evaluated in rats with intraperitoneal (i.p.) and per oral (p.o.)dosing. RESULTS Structure-activity relationship studies led to potent dual RORα/RORγ inverse agonists as well as RORα-selective inverse agonists (20, 28). LXR activity could be reduced by removing the sulfonamide nitrogen substituent. Attempts to improve the potency of these selective leads by varying substitution patterns throughout the molecule proved challenging. CONCLUSION The synthetic RORα-selective inverse agonists identified (20, 28) can be utilized as chemical tools to probe the function of RORα in vitro and in vivo.
Collapse
Affiliation(s)
- Christelle Doebelin
- Molecular Medicine, The Scripps Research Institute, Jupiter, FL 33458, United States
| | - Yuanjun He
- Molecular Medicine, The Scripps Research Institute, Jupiter, FL 33458, United States
| | - Sean Campbell
- Immunology & Microbiology, The Scripps Research Institute, Jupiter, FL 33458, United States
| | - Philippe Nuhant
- Departments of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, United States
| | - Naresh Kumar
- Molecular Medicine, The Scripps Research Institute, Jupiter, FL 33458, United States
| | - Marcel Koenig
- Molecular Medicine, The Scripps Research Institute, Jupiter, FL 33458, United States
| | - Ruben Garcia-Ordonez
- Molecular Medicine, The Scripps Research Institute, Jupiter, FL 33458, United States
| | - Mi Ra Chang
- Molecular Medicine, The Scripps Research Institute, Jupiter, FL 33458, United States
| | - William R Roush
- Departments of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, United States
| | - Li Lin
- Molecular Medicine, The Scripps Research Institute, Jupiter, FL 33458, United States
| | - Susan Kahn
- Molecular Medicine, The Scripps Research Institute, Jupiter, FL 33458, United States
| | - Michael D Cameron
- Molecular Medicine, The Scripps Research Institute, Jupiter, FL 33458, United States
| | - Patrick R Griffin
- Molecular Medicine, The Scripps Research Institute, Jupiter, FL 33458, United States
| | - Laura A Solt
- Immunology & Microbiology, The Scripps Research Institute, Jupiter, FL 33458, United States
| | - Theodore M Kamenecka
- Molecular Medicine, The Scripps Research Institute, Jupiter, FL 33458, United States
| |
Collapse
|
22
|
Yang X, Yang W, Yao Y, Deng Y, Zuo X, Yang D. Water-Promoted Ir-Catalyzed Ring-Opening of Oxa(aza)benzonorbornadienes with Fluoroalkylamines. J Org Chem 2018; 83:10097-10106. [DOI: 10.1021/acs.joc.8b01396] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Xin Yang
- Key Laboratory of Theoretical Chemistry of Environment, Ministry of Education, School of Chemistry and Environment, South China Normal University, Guangzhou 510006, People’s Republic of China
| | - Wen Yang
- Key Laboratory of Theoretical Chemistry of Environment, Ministry of Education, School of Chemistry and Environment, South China Normal University, Guangzhou 510006, People’s Republic of China
| | - Yongqi Yao
- Key Laboratory of Theoretical Chemistry of Environment, Ministry of Education, School of Chemistry and Environment, South China Normal University, Guangzhou 510006, People’s Republic of China
| | - Yingying Deng
- Key Laboratory of Theoretical Chemistry of Environment, Ministry of Education, School of Chemistry and Environment, South China Normal University, Guangzhou 510006, People’s Republic of China
| | - Xiongjun Zuo
- Key Laboratory of Theoretical Chemistry of Environment, Ministry of Education, School of Chemistry and Environment, South China Normal University, Guangzhou 510006, People’s Republic of China
| | - Dingqiao Yang
- Key Laboratory of Theoretical Chemistry of Environment, Ministry of Education, School of Chemistry and Environment, South China Normal University, Guangzhou 510006, People’s Republic of China
| |
Collapse
|
23
|
Pandya VB, Kumar S, Sachchidanand, Sharma R, Desai RC. Combating Autoimmune Diseases With Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc) Inhibitors: Hits and Misses. J Med Chem 2018; 61:10976-10995. [DOI: 10.1021/acs.jmedchem.8b00588] [Citation(s) in RCA: 74] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Vrajesh B. Pandya
- Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad 382210, India
| | - Sanjay Kumar
- Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad 382210, India
| | - Sachchidanand
- Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad 382210, India
| | - Rajiv Sharma
- Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad 382210, India
| | - Ranjit C. Desai
- Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH8A, Moraiya, Ahmedabad 382210, India
| |
Collapse
|
24
|
Koyama R, Fukuda Y, Kamada Y, Nakagawa H, Witmer D, Ambrus-Aikelin G, Sang BC, Nakayama M, Iwata H. Cholesterol Unbound RORγt Protein Enables a Sensitive Inverse Agonist Screening. Assay Drug Dev Technol 2018; 16:194-204. [PMID: 29874096 DOI: 10.1089/adt.2018.852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The retinoic acid-related orphan receptor gamma T (RORγt) plays an important role in Th17 cell proliferation and functionality. Thus, RORγt inverse agonists are thought to be potent therapeutic agents for Th17-mediated autoimmune diseases, such as rheumatoid arthritis, asthma, inflammatory bowel disease, and psoriasis. Although RORγt has constitutive activity, it is recognized that the receptor is physiologically regulated by various cholesterol derivatives. In this study, we sought to identify RORγt inverse agonists through a high-throughput screening campaign. To this end, we compared an apo-RORγt protein from Escherichia coli and a cholesterol-bound RORγt protein from insect cells. The IC50 of the known RORγt inverse agonist TO901317 was significantly lower for the apoprotein than for the cholesterol-bound RORγt. Through high-throughput screening using a fluorescence-based cholesterol binding assay with the apoprotein, we identified compound 1 as a novel cholesterol-competitive RORγt inverse agonist. Compound 1 inhibited the RORγt-TopFluor cholesterol interaction, coactivator recruitment, and transcriptional activity of RORγt. Cell-based reporter gene assay demonstrated that compound 1 showed higher potency by lipid depletion treatment. Collectively, our findings indicate that eliminating cholesterol from the RORγt protein is suitable for sensitive high-throughput screening to identify RORγt inverse agonists.
Collapse
Affiliation(s)
- Ryokichi Koyama
- 1 Biomolecular Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , Fujisawa, Japan
| | - Yasunori Fukuda
- 1 Biomolecular Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , Fujisawa, Japan
| | - Yusuke Kamada
- 1 Biomolecular Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , Fujisawa, Japan
| | - Hideyuki Nakagawa
- 1 Biomolecular Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , Fujisawa, Japan
| | - Darbi Witmer
- 2 Department of Structural Biology, Takeda California , San Diego, California
| | - Geza Ambrus-Aikelin
- 2 Department of Structural Biology, Takeda California , San Diego, California
| | - Bi-Ching Sang
- 2 Department of Structural Biology, Takeda California , San Diego, California
| | - Masaharu Nakayama
- 1 Biomolecular Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , Fujisawa, Japan
| | - Hidehisa Iwata
- 1 Biomolecular Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , Fujisawa, Japan
| |
Collapse
|
25
|
Targeting RORs nuclear receptors by novel synthetic steroidal inverse agonists for autoimmune disorders. Bioorg Med Chem 2018; 26:1686-1704. [DOI: 10.1016/j.bmc.2018.02.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Revised: 02/01/2018] [Accepted: 02/13/2018] [Indexed: 11/19/2022]
|
26
|
Ouvry G, Atrux-Tallau N, Bihl F, Bondu A, Bouix-Peter C, Carlavan I, Christin O, Cuadrado MJ, Defoin-Platel C, Deret S, Duvert D, Feret C, Forissier M, Fournier JF, Froude D, Hacini-Rachinel F, Harris CS, Hervouet C, Huguet H, Lafitte G, Luzy AP, Musicki B, Orfila D, Ozello B, Pascau C, Pascau J, Parnet V, Peluchon G, Pierre R, Piwnica D, Raffin C, Rossio P, Spiesse D, Taquet N, Thoreau E, Vatinel R, Vial E, Hennequin LF. Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis. ChemMedChem 2018; 13:321-337. [PMID: 29327456 DOI: 10.1002/cmdc.201700758] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Revised: 01/05/2018] [Indexed: 01/12/2023]
Abstract
With possible implications in multiple autoimmune diseases, the retinoic acid receptor-related orphan receptor RORγ has become a sought-after target in the pharmaceutical industry. Herein are described the efforts to identify a potent RORγ inverse agonist compatible with topical application for the treatment of skin diseases. These efforts culminated in the discovery of N-(2,4-dimethylphenyl)-N-isobutyl-2-oxo-1-[(tetrahydro-2H-pyran-4-yl)methyl]-2,3-dihydro-1H-benzo[d]imidazole-5-sulfonamide (CD12681), a potent inverse agonist with in vivo activity in an IL-23-induced mouse skin inflammation model.
Collapse
Affiliation(s)
- Gilles Ouvry
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Nicolas Atrux-Tallau
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Franck Bihl
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Aline Bondu
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Claire Bouix-Peter
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Isabelle Carlavan
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Olivier Christin
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Marie-Josée Cuadrado
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Claire Defoin-Platel
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Sophie Deret
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Denis Duvert
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Christophe Feret
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Mathieu Forissier
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Jean-François Fournier
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - David Froude
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Fériel Hacini-Rachinel
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Craig Steven Harris
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Catherine Hervouet
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Hélène Huguet
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Guillaume Lafitte
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Anne-Pascale Luzy
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Branislav Musicki
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Danielle Orfila
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Benjamin Ozello
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Coralie Pascau
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Jonathan Pascau
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Véronique Parnet
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Guillaume Peluchon
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Romain Pierre
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - David Piwnica
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Catherine Raffin
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Patricia Rossio
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Delphine Spiesse
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Nathalie Taquet
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Etienne Thoreau
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Rodolphe Vatinel
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | - Emmanuel Vial
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902, Sophia-Antipolis Cedex, France
| | | |
Collapse
|
27
|
Gong H, Weinstein DS, Lu Z, Duan JJW, Stachura S, Haque L, Karmakar A, Hemagiri H, Raut DK, Gupta AK, Khan J, Camac D, Sack JS, Pudzianowski A, Wu DR, Yarde M, Shen DR, Borowski V, Xie JH, Sun H, D'Arienzo C, Dabros M, Galella MA, Wang F, Weigelt CA, Zhao Q, Foster W, Somerville JE, Salter-Cid LM, Barrish JC, Carter PH, Dhar TGM. Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORγ/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity. Bioorg Med Chem Lett 2018; 28:85-93. [PMID: 29233651 DOI: 10.1016/j.bmcl.2017.12.006] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Revised: 11/18/2017] [Accepted: 12/04/2017] [Indexed: 02/04/2023]
Abstract
We disclose the optimization of a high throughput screening hit to yield benzothiazine and tetrahydroquinoline sulfonamides as potent RORγt inverse agonists. However, a majority of these compounds showed potent activity against pregnane X receptor (PXR) and modest activity against liver X receptor α (LXRα). Structure-based drug design (SBDD) led to the identification of benzothiazine and tetrahydroquinoline sulfonamide analogs which completely dialed out LXRα activity and were less potent at PXR. Pharmacodynamic (PD) data for compound 35 in an IL-23 induced IL-17 mouse model is discussed along with the implications of a high Ymax in the PXR assay for long term preclinical pharmacokinetic (PK) studies.
Collapse
Affiliation(s)
- Hua Gong
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - David S Weinstein
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Zhonghui Lu
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - James J-W Duan
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Sylwia Stachura
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Lauren Haque
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Ananta Karmakar
- Bristol-Myers Squibb-Biocon Research Center, Bangalore, India
| | | | | | | | - Javed Khan
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Dan Camac
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - John S Sack
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Andrew Pudzianowski
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Dauh-Rurng Wu
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Melissa Yarde
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Ding-Ren Shen
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Virna Borowski
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Jenny H Xie
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Huadong Sun
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Celia D'Arienzo
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Marta Dabros
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Michael A Galella
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Faye Wang
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Carolyn A Weigelt
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Qihong Zhao
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - William Foster
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - John E Somerville
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Luisa M Salter-Cid
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Joel C Barrish
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Percy H Carter
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - T G Murali Dhar
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
| |
Collapse
|
28
|
Ramesh R, Reddy DS. Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds. J Med Chem 2017; 61:3779-3798. [DOI: 10.1021/acs.jmedchem.7b00718] [Citation(s) in RCA: 203] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Remya Ramesh
- CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pune, 411008, India
- Academy of Scientific and Innovative Research (AcSIR), New Delhi, 110 025, India
| | - D. Srinivasa Reddy
- CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pune, 411008, India
- Academy of Scientific and Innovative Research (AcSIR), New Delhi, 110 025, India
| |
Collapse
|
29
|
Masson GR, Jenkins ML, Burke JE. An overview of hydrogen deuterium exchange mass spectrometry (HDX-MS) in drug discovery. Expert Opin Drug Discov 2017; 12:981-994. [PMID: 28770632 DOI: 10.1080/17460441.2017.1363734] [Citation(s) in RCA: 89] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
INTRODUCTION Hydrogen deuterium exchange mass spectrometry (HDX-MS) is a powerful methodology to study protein dynamics, protein folding, protein-protein interactions, and protein small molecule interactions. The development of novel methodologies and technical advancements in mass spectrometers has greatly expanded the accessibility and acceptance of this technique within both academia and industry. Areas covered: This review examines the theoretical basis of how amide exchange occurs, how different mass spectrometer approaches can be used for HDX-MS experiments, as well as the use of HDX-MS in drug development, specifically focusing on how HDX-MS is used to characterize bio-therapeutics, and its use in examining protein-protein and protein small molecule interactions. Expert opinion: HDX-MS has been widely accepted within the pharmaceutical industry for the characterization of bio-therapeutics as well as in the mapping of antibody drug epitopes. However, there is room for this technique to be more widely used in the drug discovery process. This is particularly true in the use of HDX-MS as a complement to other high-resolution structural approaches, as well as in the development of small molecule therapeutics that can target both active-site and allosteric binding sites.
Collapse
Affiliation(s)
- Glenn R Masson
- a Protein and Nucleic Acid Chemistry Division , MRC Laboratory of Molecular Biology , Cambridge , UK
| | - Meredith L Jenkins
- b Department of Biochemistry and Microbiology , University of Victoria , Victoria , Canada
| | - John E Burke
- b Department of Biochemistry and Microbiology , University of Victoria , Victoria , Canada
| |
Collapse
|
30
|
Kallen J, Izaac A, Be C, Arista L, Orain D, Kaupmann K, Guntermann C, Hoegenauer K, Hintermann S. Structural States of RORγt: X-ray Elucidation of Molecular Mechanisms and Binding Interactions for Natural and Synthetic Compounds. ChemMedChem 2017; 12:1014-1021. [PMID: 28590087 DOI: 10.1002/cmdc.201700278] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2017] [Revised: 06/07/2017] [Indexed: 12/11/2022]
Abstract
The T-cell-specific retinoic acid receptor (RAR)-related orphan receptor-γ (RORγt) is a key transcription factor for the production of pro-inflammatory Th17 cytokines, which are implicated in the pathogenesis of autoimmune diseases. Over the years, several structurally diverse RORγt inverse agonists have been reported, but combining high potency and good physicochemical properties has remained a challenging task. We recently reported a new series of inverse agonists based on an imidazopyridine core with good physicochemical properties and excellent selectivity. Herein we report eight new X-ray crystal structures for different classes of natural and synthetic compounds, including examples selected from the patent literature. Analysis of their respective binding modes revealed insight into the molecular mechanisms that lead to agonism, antagonism, or inverse agonism. We report new molecular mechanisms for RORγt agonism and propose a separation of the inverse agonists into two classes: those that act via steric clash and those that act via other mechanisms (for the latter, co-crystallization with a co-activator peptide and helix 12 in the agonist position is still possible). For the non-steric clash inverse agonists, we propose a new mechanism ("water trapping") which can be combined with other mechanisms (e.g., close contacts with H479). In addition, we compare the interactions made for selected compounds in the "back pocket" near S404 and in the "sulfate pocket" near R364 and R367. Taken together, these new mechanistic insights should prove useful for the design and optimization of further RORγt modulators.
Collapse
Affiliation(s)
- Joerg Kallen
- CBT, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Aude Izaac
- CBT, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Celine Be
- CBT, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Luca Arista
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - David Orain
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Klemens Kaupmann
- ATI, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Christine Guntermann
- ATI, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Klemens Hoegenauer
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| | - Samuel Hintermann
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland
| |
Collapse
|
31
|
Li X, Anderson M, Collin D, Muegge I, Wan J, Brennan D, Kugler S, Terenzio D, Kennedy C, Lin S, Labadia ME, Cook B, Hughes R, Farrow NA. Structural studies unravel the active conformation of apo RORγt nuclear receptor and a common inverse agonism of two diverse classes of RORγt inhibitors. J Biol Chem 2017; 292:11618-11630. [PMID: 28546429 DOI: 10.1074/jbc.m117.789024] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2017] [Revised: 05/23/2017] [Indexed: 12/31/2022] Open
Abstract
The nuclear receptor retinoid acid receptor-related orphan receptor γt (RORγt) is a master regulator of the Th17/IL-17 pathway that plays crucial roles in the pathogenesis of autoimmunity. RORγt has recently emerged as a highly promising target for treatment of a number of autoimmune diseases. Through high-throughput screening, we previously identified several classes of inverse agonists for RORγt. Here, we report the crystal structures for the ligand-binding domain of RORγt in both apo and ligand-bound states. We show that apo RORγt adopts an active conformation capable of recruiting coactivator peptides and present a detailed analysis of the structural determinants that stabilize helix 12 (H12) of RORγt in the active state in the absence of a ligand. The structures of ligand-bound RORγt reveal that binding of the inverse agonists disrupts critical interactions that stabilize H12. This destabilizing effect is supported by ab initio calculations and experimentally by a normalized crystallographic B-factor analysis. Of note, the H12 destabilization in the active state shifts the conformational equilibrium of RORγt toward an inactive state, which underlies the molecular mechanism of action for the inverse agonists reported here. Our findings highlight that nuclear receptor structure and function are dictated by a dynamic conformational equilibrium and that subtle changes in ligand structures can shift this equilibrium in opposite directions, leading to a functional switch from agonists to inverse agonists.
Collapse
Affiliation(s)
- Xiang Li
- Departments of Small Molecule Discovery Research, Ridgefield, Connecticut 06877-0368.
| | - Marie Anderson
- Departments of Small Molecule Discovery Research, Ridgefield, Connecticut 06877-0368
| | - Delphine Collin
- Departments of Small Molecule Discovery Research, Ridgefield, Connecticut 06877-0368
| | - Ingo Muegge
- Departments of Small Molecule Discovery Research, Ridgefield, Connecticut 06877-0368
| | - John Wan
- Departments of Small Molecule Discovery Research, Ridgefield, Connecticut 06877-0368
| | - Debra Brennan
- Departments of Small Molecule Discovery Research, Ridgefield, Connecticut 06877-0368
| | - Stanley Kugler
- Departments of Small Molecule Discovery Research, Ridgefield, Connecticut 06877-0368
| | - Donna Terenzio
- Departments of Small Molecule Discovery Research, Ridgefield, Connecticut 06877-0368
| | - Charles Kennedy
- Departments of Small Molecule Discovery Research, Ridgefield, Connecticut 06877-0368
| | - Siqi Lin
- Departments of Small Molecule Discovery Research, Ridgefield, Connecticut 06877-0368
| | - Mark E Labadia
- Immunology and Respiratory Diseases, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877-0368
| | - Brian Cook
- Departments of Small Molecule Discovery Research, Ridgefield, Connecticut 06877-0368
| | - Robert Hughes
- Departments of Small Molecule Discovery Research, Ridgefield, Connecticut 06877-0368
| | - Neil A Farrow
- Departments of Small Molecule Discovery Research, Ridgefield, Connecticut 06877-0368
| |
Collapse
|
32
|
Saltzberg DJ, Broughton HB, Pellarin R, Chalmers MJ, Espada A, Dodge JA, Pascal BD, Griffin PR, Humblet C, Sali A. A Residue-Resolved Bayesian Approach to Quantitative Interpretation of Hydrogen-Deuterium Exchange from Mass Spectrometry: Application to Characterizing Protein-Ligand Interactions. J Phys Chem B 2016; 121:3493-3501. [PMID: 27807976 DOI: 10.1021/acs.jpcb.6b09358] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Characterization of interactions between proteins and other molecules is crucial for understanding the mechanisms of action of biological systems and, thus, drug discovery. An increasingly useful approach to mapping these interactions is measurement of hydrogen/deuterium exchange (HDX) using mass spectrometry (HDX-MS), which measures the time-resolved deuterium incorporation of peptides obtained by enzymatic digestion of the protein. Comparison of exchange rates between apo- and ligand-bound conditions results in a mapping of the differential HDX (ΔHDX) of the ligand. Residue-level analysis of these data, however, must account for experimental error, sparseness, and ambiguity due to overlapping peptides. Here, we propose a Bayesian method consisting of a forward model, noise model, prior probabilities, and a Monte Carlo sampling scheme. This method exploits a residue-resolved exponential rate model of HDX-MS data obtained from all peptides simultaneously, and explicitly models experimental error. The result is the best possible estimate of ΔHDX magnitude and significance for each residue given the data. We demonstrate the method by revealing richer structural interpretation of ΔHDX data on two nuclear receptors: vitamin D-receptor (VDR) and retinoic acid receptor gamma (RORγ). The method is implemented in HDX Workbench and as a standalone module of the open source Integrative Modeling Platform.
Collapse
Affiliation(s)
- Daniel J Saltzberg
- Department of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, and California Institute for Quantitative Biosciences (QB3), University of California, San Francisco , San Francisco, California, United States
| | - Howard B Broughton
- Centro de Investigación Lilly, SA , Avenida de la Industria 30, 28108 Alcobendas, Spain
| | - Riccardo Pellarin
- Department of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, and California Institute for Quantitative Biosciences (QB3), University of California, San Francisco , San Francisco, California, United States.,Structural Bioinformatics Unit, Institut Pasteur, CNRS UMR 3528 , Paris, France
| | - Michael J Chalmers
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana, United States
| | - Alfonso Espada
- Centro de Investigación Lilly, SA , Avenida de la Industria 30, 28108 Alcobendas, Spain
| | - Jeffrey A Dodge
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana, United States
| | - Bruce D Pascal
- Bioinformatics Core, The Scripps Research Institute-Scripps Florida , Jupiter, Florida, United States
| | - Patrick R Griffin
- Department of Molecular Therapeutics, The Scripps Research Institute-Scripps Florida , Jupiter, Florida, United States
| | - Christine Humblet
- Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, Indiana, United States
| | - Andrej Sali
- Department of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, and California Institute for Quantitative Biosciences (QB3), University of California, San Francisco , San Francisco, California, United States
| |
Collapse
|
33
|
Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-ones as RORc inverse agonists. Acta Pharmacol Sin 2016; 37:1516-1524. [PMID: 27374490 DOI: 10.1038/aps.2016.32] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Accepted: 04/05/2016] [Indexed: 01/01/2023] Open
Abstract
AIM Retinoic acid receptor-related orphan nuclear receptors (RORs) are orphan nuclear receptors that show constitutive activity in the absence of ligands. Among 3 subtypes of RORs, RORc is a promising therapeutic target for the treatment of Th17-mediated autoimmune diseases. Here, we report novel RORc inverse agonists discovered through structure-based drug design. METHODS Based on the structure of compound 8, a previously described agonist of RORa, a series of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one derivatives were designed and synthesized. The interaction between the compounds and RORc was detected at molecular level using AlphaScreen assay. The compounds were further examined in 293T cells transfected with RORc and luciferase reporter gene. Thermal stability shift assay was used to evaluate the effects of the compounds on protein stability. RESULTS A total of 27 derivatives were designed and synthesized. Among them, the compound 22b was identified as the most potent RORc inverse agonist. Its IC50 values were 2.39 μmol/L in AlphaScreen assay, and 0.82 μmol/L in inhibition of the cell-based luciferase reporter activity. Furthermore, the compound 22b displayed a 120-fold selectivity for RORc over other nuclear receptors. Moreover, a molecular docking study showed that the structure-activity relationship was consistent with the binding mode of compound 22b in RORc. CONCLUSION 4-(4-(Benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one derivatives are promising candidates for the treatment of Th17-mediated autoimmune diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Collapse
|
34
|
Padala AK, Wani A, Vishwakarma RA, Kumar A, Bharate SB. Functional induction of P-glycoprotein efflux pump by phenyl benzenesulfonamides: Synthesis and biological evaluation of T0901317 analogs. Eur J Med Chem 2016; 122:744-755. [PMID: 27497733 DOI: 10.1016/j.ejmech.2016.07.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2016] [Revised: 06/17/2016] [Accepted: 07/05/2016] [Indexed: 10/21/2022]
Abstract
N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide (T0901317, 6) is a potent activator of pregnane-X-receptor (PXR), which is a nuclear receptor controlling P-gp expression. Herein, we aimed to investigate P-gp induction activity of T0901317 and establish its structure-activity relationship. T0901317 along with a series of N-triazolyl-methylene-linked benzenesulfonamides were synthesized and screened for P-gp induction activity using a rhodamine-123 based efflux assay in the P-gp overexpressing human adenocarcinoma LS-180 cells, wherein several compounds showed potent P-gp induction activity at 5 μM. Treatment with benzene sulphonamides led to the decrease in intracellular accumulation of a fluorescent P-gp substrate rhodamine-123 up to 48% (control 100%). In the western-blot studies, T0901317 (6) and its triazole linked analog 26e at 5 μM displayed induction of P-gp expression in LS180 cells. These compounds were non-toxic in LS-180 and human neuroblastoma SH-SY5Y cells (IC50 > 50 μM). The compound 26e showed significant P-gp induction even at 0.3 μM, indicating an excellent therapeutic window. These results clearly indicate promise of this class of compounds as potential agents to enhance amyloid-β clearance in Alzheimers patients.
Collapse
Affiliation(s)
- Anil K Padala
- Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India; Academy of Scientific & Innovative Research (AcSIR), CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India
| | - Abubakar Wani
- Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India
| | - Ram A Vishwakarma
- Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India; Academy of Scientific & Innovative Research (AcSIR), CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India
| | - Ajay Kumar
- Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India.
| | - Sandip B Bharate
- Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India; Academy of Scientific & Innovative Research (AcSIR), CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India.
| |
Collapse
|
35
|
Discovery of oxa-sultams as RORc inverse agonists showing reduced lipophilicity, improved selectivity and favorable ADME properties. Bioorg Med Chem Lett 2016; 26:4455-4461. [DOI: 10.1016/j.bmcl.2016.07.081] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2016] [Revised: 07/29/2016] [Accepted: 07/30/2016] [Indexed: 12/14/2022]
|
36
|
Structural determinant for inducing RORgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand. BMC STRUCTURAL BIOLOGY 2016; 16:7. [PMID: 27246200 PMCID: PMC4888278 DOI: 10.1186/s12900-016-0059-3] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/26/2015] [Accepted: 05/18/2016] [Indexed: 12/24/2022]
Abstract
Background The nuclear hormone receptor RORγ regulates transcriptional genes involved in the production of the pro-inflammatory interleukin IL-17 which has been linked to autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. This transcriptional activity of RORγ is modulated through a protein-protein interaction involving the activation function 2 (AF2) helix on the ligand binding domain of RORγ and a conserved LXXLL helix motif on coactivator proteins. Our goal was to develop a RORγ specific inverse agonist that would help down regulate pro-inflammatory gene transcription by disrupting the protein protein interaction with coactivator proteins as a therapeutic agent. Results We identified a novel series of synthetic benzoxazinone ligands having an agonist (BIO592) and inverse agonist (BIO399) mode of action in a FRET based assay. We show that the AF2 helix of RORγ is proteolytically sensitive when inverse agonist BIO399 binds. Using x-ray crystallography we show how small modifications on the benzoxazinone agonist BIO592 trigger inverse agonism of RORγ. Using an in vivo reporter assay, we show that the inverse agonist BIO399 displayed specificity for RORγ over ROR sub-family members α and β. Conclusion The synthetic benzoxazinone ligands identified in our FRET assay have an agonist (BIO592) or inverse agonist (BIO399) effect by stabilizing or destabilizing the agonist conformation of RORγ. The proteolytic sensitivity of the AF2 helix of RORγ demonstrates that it destabilizes upon BIO399 inverse agonist binding perturbing the coactivator protein binding site. Our structural investigation of the BIO592 agonist and BIO399 inverse agonist structures identified residue Met358 on RORγ as the trigger for RORγ specific inverse agonism. Electronic supplementary material The online version of this article (doi:10.1186/s12900-016-0059-3) contains supplementary material, which is available to authorized users.
Collapse
|
37
|
Altered activity profile of a tertiary silanol analog of multi-targeting nuclear receptor modulator T0901317. Bioorg Med Chem Lett 2016; 26:1817-20. [DOI: 10.1016/j.bmcl.2016.02.031] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2016] [Revised: 02/09/2016] [Accepted: 02/12/2016] [Indexed: 11/20/2022]
|
38
|
Hirata K, Kotoku M, Seki N, Maeba T, Maeda K, Hirashima S, Sakai T, Obika S, Hori A, Hase Y, Yamaguchi T, Katsuda Y, Hata T, Miyagawa N, Arita K, Nomura Y, Asahina K, Aratsu Y, Kamada M, Adachi T, Noguchi M, Doi S, Crowe P, Bradley E, Steensma R, Tao H, Fenn M, Babine R, Li X, Thacher S, Hashimoto H, Shiozaki M. SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious RORγ Inhibitor. ACS Med Chem Lett 2016; 7:23-7. [PMID: 26819660 DOI: 10.1021/acsmedchemlett.5b00253] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Accepted: 11/04/2015] [Indexed: 11/28/2022] Open
Abstract
A novel series of RORγ inhibitors was identified starting with the HTS hit 1. After SAR investigation based on a prospective consideration of two drug-likeness metrics, ligand efficiency (LE) and fraction of sp(3) carbon atoms (Fsp(3)), significant improvement of metabolic stability as well as reduction of CYP inhibition was observed, which finally led to discovery of a selective and orally efficacious RORγ inhibitor 3z.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Masafumi Kamada
- Pharmaceutical Frontier
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-13-2, Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan
| | - Tsuyoshi Adachi
- Pharmaceutical Frontier
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-13-2, Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan
| | - Masato Noguchi
- Pharmaceutical Frontier
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-13-2, Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan
| | - Satoki Doi
- Pharmaceutical Frontier
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-13-2, Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan
| | - Paul Crowe
- Orphagen Pharmaceuticals, 11558 Sorrento Valley Road, Suite
4, San Diego, California 92121, United States
| | - Erin Bradley
- Orphagen Pharmaceuticals, 11558 Sorrento Valley Road, Suite
4, San Diego, California 92121, United States
| | - Ruo Steensma
- Orphagen Pharmaceuticals, 11558 Sorrento Valley Road, Suite
4, San Diego, California 92121, United States
| | - Haiyan Tao
- Orphagen Pharmaceuticals, 11558 Sorrento Valley Road, Suite
4, San Diego, California 92121, United States
| | - Morgan Fenn
- Orphagen Pharmaceuticals, 11558 Sorrento Valley Road, Suite
4, San Diego, California 92121, United States
| | - Robert Babine
- Orphagen Pharmaceuticals, 11558 Sorrento Valley Road, Suite
4, San Diego, California 92121, United States
| | - Xiaolin Li
- Orphagen Pharmaceuticals, 11558 Sorrento Valley Road, Suite
4, San Diego, California 92121, United States
| | - Scott Thacher
- Orphagen Pharmaceuticals, 11558 Sorrento Valley Road, Suite
4, San Diego, California 92121, United States
| | | | | |
Collapse
|
39
|
Identification of an allosteric binding site for RORγt inhibition. Nat Commun 2015; 6:8833. [PMID: 26640126 PMCID: PMC4686831 DOI: 10.1038/ncomms9833] [Citation(s) in RCA: 82] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2015] [Accepted: 10/08/2015] [Indexed: 01/02/2023] Open
Abstract
RORγt is critical for the differentiation and proliferation of Th17 cells associated with several chronic autoimmune diseases. We report the discovery of a novel allosteric binding site on the nuclear receptor RORγt. Co-crystallization of the ligand binding domain (LBD) of RORγt with a series of small-molecule antagonists demonstrates occupancy of a previously unreported allosteric binding pocket. Binding at this non-canonical site induces an unprecedented conformational reorientation of helix 12 in the RORγt LBD, which blocks cofactor binding. The functional consequence of this allosteric ligand-mediated conformation is inhibition of function as evidenced by both biochemical and cellular studies. RORγt function is thus antagonized in a manner molecularly distinct from that of previously described orthosteric RORγt ligands. This brings forward an approach to target RORγt for the treatment of Th17-mediated autoimmune diseases. The elucidation of an unprecedented modality of pharmacological antagonism establishes a mechanism for modulation of nuclear receptors.
Collapse
|
40
|
Fauber BP, Gobbi A, Savy P, Burton B, Deng Y, Everett C, La H, Johnson AR, Lockey P, Norman M, Wong H. Identification of N-sulfonyl-tetrahydroquinolines as RORc inverse agonists. Bioorg Med Chem Lett 2015; 25:4109-13. [DOI: 10.1016/j.bmcl.2015.08.028] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2015] [Revised: 08/06/2015] [Accepted: 08/10/2015] [Indexed: 12/14/2022]
|
41
|
Discovery of N -(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent RORγt inverse agonists. Bioorg Med Chem 2015; 23:5293-302. [DOI: 10.1016/j.bmc.2015.07.068] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2015] [Revised: 07/29/2015] [Accepted: 07/30/2015] [Indexed: 11/22/2022]
|
42
|
Wang Y, Cai W, Cheng Y, Yang T, Liu Q, Zhang G, Meng Q, Han F, Huang Y, Zhou L, Xiang Z, Zhao YG, Xu Y, Cheng Z, Lu S, Wu Q, Xiang JN, Elliott JD, Leung S, Ren F, Lin X. Discovery of Biaryl Amides as Potent, Orally Bioavailable, and CNS Penetrant RORγt Inhibitors. ACS Med Chem Lett 2015; 6:787-92. [PMID: 26191367 DOI: 10.1021/acsmedchemlett.5b00122] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2015] [Accepted: 05/26/2015] [Indexed: 11/29/2022] Open
Abstract
A novel series of biaryl amides was identified as RORγt inhibitors through core replacement of a starting hit 1. Structure-activity relationship exploration on the biaryl moiety led to discovery of potent RORγt inhibitors with good oral bioavailability and CNS penetration. Compounds 9a and 9g demonstrated excellent in vivo efficacy in EAE mice dose dependently with once daily oral administration.
Collapse
Affiliation(s)
- Yonghui Wang
- School
of Pharmacy, Fudan University, 826 Zhangheng Road, Pudong, Shanghai 201203, China
| | - Wei Cai
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Yaobang Cheng
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Ting Yang
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Qian Liu
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Guifeng Zhang
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Qinghua Meng
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Fangbin Han
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Yafei Huang
- School
of Pharmacy, Fudan University, 826 Zhangheng Road, Pudong, Shanghai 201203, China
| | - Ling Zhou
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Zhijun Xiang
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Yong-Gang Zhao
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Yan Xu
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Ziqiang Cheng
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Sijie Lu
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Qianqian Wu
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Jia-Ning Xiang
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - John D. Elliott
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Stewart Leung
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Feng Ren
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| | - Xichen Lin
- Research
and Development, GlaxoSmithKline, No. 3 Building, 898 Halei Road, Pudong, Shanghai 201203, China
| |
Collapse
|
43
|
Design and synthesis of novel ROR inverse agonists with a dibenzosilole scaffold as a hydrophobic core structure. Bioorg Med Chem 2015; 23:2982-8. [DOI: 10.1016/j.bmc.2015.05.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2015] [Revised: 05/02/2015] [Accepted: 05/05/2015] [Indexed: 01/09/2023]
|
44
|
Abstract
We report the synthesis of fluorinated anilines by palladium-catalyzed coupling of fluoroalkylamines with aryl bromides and aryl chlorides. The products of these reactions are valuable because anilines typically require the presence of an electron-withdrawing substituent on nitrogen to suppress aerobic or metabolic oxidation, and the fluoroalkyl groups have steric properties and polarity distinct from those of more common electron-withdrawing amide and sulfonamide units. The fluoroalkylaniline products are unstable under typical conditions for C-N coupling reactions (heat and strong base). However, the reactions conducted with the weaker base KOPh, which has rarely been used in cross-coupling to form C-N bonds, occurred in high yield in the presence of a catalyst derived from commercially available AdBippyPhos and [Pd(allyl)Cl]2. Under these conditions, the reactions occur with low catalyst loadings (<0.50 mol % for most substrates) and tolerate the presence of various functional groups that react with the strong bases that are typically used in Pd-catalyzed C-N cross-coupling reactions of aryl halides. The resting state of the catalyst is the phenoxide complex, (BippyPhosPd(Ar)OPh); due to the electron-withdrawing property of the fluoroalkyl substituent, the turnover-limiting step of the reaction is reductive elimination to form the C-N bond.
Collapse
Affiliation(s)
- Andrew T Brusoe
- Department of Chemistry, University of California, Berkeley, California 94720, United States
| | - John F Hartwig
- Department of Chemistry, University of California, Berkeley, California 94720, United States
| |
Collapse
|
45
|
Fauber BP, René O, Deng Y, DeVoss J, Eidenschenk C, Everett C, Ganguli A, Gobbi A, Hawkins J, Johnson AR, La H, Lesch J, Lockey P, Norman M, Ouyang W, Summerhill S, Wong H. Discovery of 1-{4-[3-fluoro-4-((3s,6r)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C (RORc or RORγ) inverse agonist. J Med Chem 2015; 58:5308-22. [PMID: 26061388 DOI: 10.1021/acs.jmedchem.5b00597] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Retinoic acid receptor-related orphan receptor C (RORc, RORγ, or NR1F3) is a nuclear receptor that plays a major role in the production of interleukin (IL)-17. Considerable efforts have been directed toward the discovery of selective RORc inverse agonists as potential treatments of inflammatory diseases such as psoriasis and rheumatoid arthritis. Using the previously reported tertiary sulfonamide 1 as a starting point, we engineered structural modifications that significantly improved human and rat metabolic stabilities while maintaining a potent and highly selective RORc inverse agonist profile. The most advanced δ-sultam compound, GNE-3500 (27, 1-{4-[3-fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone), possessed favorable RORc cellular potency with 75-fold selectivity for RORc over other ROR family members and >200-fold selectivity over 25 additional nuclear receptors in a cell assay panel. The favorable potency, selectivity, in vitro ADME properties, in vivo PK, and dose-dependent inhibition of IL-17 in a PK/PD model support the evaluation of 27 in preclinical studies.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Arunima Ganguli
- ⊥Discovery Biology, Argenta, Units 7-9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K
| | | | - Julie Hawkins
- ⊥Discovery Biology, Argenta, Units 7-9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K
| | | | | | | | - Peter Lockey
- ⊥Discovery Biology, Argenta, Units 7-9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K
| | - Maxine Norman
- ⊥Discovery Biology, Argenta, Units 7-9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K
| | | | - Susan Summerhill
- ⊥Discovery Biology, Argenta, Units 7-9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K
| | | |
Collapse
|
46
|
Fauber BP, Gobbi A, Robarge K, Zhou A, Barnard A, Cao J, Deng Y, Eidenschenk C, Everett C, Ganguli A, Hawkins J, Johnson AR, La H, Norman M, Salmon G, Summerhill S, Ouyang W, Tang W, Wong H. Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists. Bioorg Med Chem Lett 2015; 25:2907-12. [PMID: 26048793 DOI: 10.1016/j.bmcl.2015.05.055] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2015] [Revised: 05/18/2015] [Accepted: 05/21/2015] [Indexed: 12/21/2022]
Abstract
The nuclear receptor (NR) retinoic acid receptor-related orphan receptor gamma (RORγ, RORc, or NR1F3) is a promising target for the treatment of autoimmune diseases. RORc is a critical regulator in the production of the pro-inflammatory cytokine interleukin-17. We discovered a series of potent and selective imidazo[1,5-a]pyridine and -pyrimidine RORc inverse agonists. The most potent compounds displayed >300-fold selectivity for RORc over the other ROR family members, PPARγ, and NRs in our cellular selectivity panel. The favorable potency, selectivity, and physiochemical properties of GNE-0946 (9) and GNE-6468 (28), in addition to their potent suppression of IL-17 production in human primary cells, support their use as chemical biology tools to further explore the role of RORc in human biology.
Collapse
Affiliation(s)
| | - Alberto Gobbi
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Kirk Robarge
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Aihe Zhou
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Adrian Barnard
- Argenta, Units 7-9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, UK
| | - Jianhua Cao
- ChemPartner, No. 5 Building, 998 Halei Road, Zhangjiang Hi-Tech Park Pudong New Area, Shanghai 201203, China
| | - Yuzhong Deng
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | | | | | - Arunima Ganguli
- Argenta, Units 7-9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, UK
| | - Julie Hawkins
- Argenta, Units 7-9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, UK
| | - Adam R Johnson
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Hank La
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Maxine Norman
- Argenta, Units 7-9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, UK
| | - Gary Salmon
- Argenta, Units 7-9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, UK
| | - Susan Summerhill
- Argenta, Units 7-9 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, UK
| | - Wenjun Ouyang
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | - Wei Tang
- ChemPartner, No. 5 Building, 998 Halei Road, Zhangjiang Hi-Tech Park Pudong New Area, Shanghai 201203, China
| | - Harvey Wong
- Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| |
Collapse
|
47
|
Discovery of 1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide analogs as new RORC modulators. Bioorg Med Chem Lett 2015; 25:1892-5. [DOI: 10.1016/j.bmcl.2015.03.042] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2015] [Revised: 03/12/2015] [Accepted: 03/16/2015] [Indexed: 11/22/2022]
|
48
|
René O, Fauber B, Boenig GL, Burton B, Eidenschenk C, Everett C, Gobbi A, Hymowitz SG, Johnson AR, Kiefer JR, Liimatta M, Lockey P, Norman M, Ouyang W, Wallweber HA, Wong H. Minor Structural Change to Tertiary Sulfonamide RORc Ligands Led to Opposite Mechanisms of Action. ACS Med Chem Lett 2015; 6:276-81. [PMID: 25815138 PMCID: PMC4360161 DOI: 10.1021/ml500420y] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2014] [Accepted: 12/04/2014] [Indexed: 12/21/2022] Open
Abstract
A minor structural change to tertiary sulfonamide RORc ligands led to distinct mechanisms of action. Co-crystal structures of two compounds revealed mechanistically consistent protein conformational changes. Optimized phenylsulfonamides were identified as RORc agonists while benzylsulfonamides exhibited potent inverse agonist activity. Compounds behaving as agonists in our biochemical assay also gave rise to an increased production of IL-17 in human PBMCs whereas inverse agonists led to significant suppression of IL-17 under the same assay conditions. The most potent inverse agonist compound showed >180-fold selectivity over the ROR isoforms as well as all other nuclear receptors that were profiled.
Collapse
Affiliation(s)
- Olivier René
- Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
| | - Benjamin
P. Fauber
- Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
| | | | - Brenda Burton
- Argenta, Early
Discovery, Charles River, 7-9 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
| | - Céline Eidenschenk
- Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
| | - Christine Everett
- Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
| | - Alberto Gobbi
- Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
| | - Sarah G. Hymowitz
- Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
| | - Adam R. Johnson
- Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
| | - James R. Kiefer
- Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
| | - Marya Liimatta
- Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
| | - Peter Lockey
- Argenta, Early
Discovery, Charles River, 7-9 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
| | - Maxine Norman
- Argenta, Early
Discovery, Charles River, 7-9 Spire
Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
| | - Wenjun Ouyang
- Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
| | - Heidi A. Wallweber
- Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
| | - Harvey Wong
- Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080, United States
| |
Collapse
|
49
|
ROR nuclear receptors: structures, related diseases, and drug discovery. Acta Pharmacol Sin 2015; 36:71-87. [PMID: 25500868 DOI: 10.1038/aps.2014.120] [Citation(s) in RCA: 98] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2014] [Accepted: 10/08/2014] [Indexed: 12/31/2022] Open
Abstract
Nuclear receptors (NRs) are ligand-regulated transcription factors that regulate metabolism, development and immunity. The NR superfamily is one of the major classes of drug targets for human diseases. Retinoic acid receptor-related orphan receptor (ROR) α, β and γ belong to the NR superfamily, and these receptors are still considered as 'orphan' receptors because the identification of their endogenous ligands has been controversial. Recent studies have demonstrated that these receptors are regulated by synthetic ligands, thus emerge as important drug targets for the treatment of multiple sclerosis, rheumatoid arthritis, psoriasis, etc. Studying the structural basis and ligand development of RORs will pave the way for a better understanding of the roles of these receptors in human diseases. Here, we review the structural basis, disease relevance, strategies for ligand identification, and current status of development of therapeutic ligands for RORs.
Collapse
|
50
|
Gallastegui N, Mackinnon JAG, Fletterick RJ, Estébanez-Perpiñá E. Advances in our structural understanding of orphan nuclear receptors. Trends Biochem Sci 2014; 40:25-35. [PMID: 25499868 DOI: 10.1016/j.tibs.2014.11.002] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2014] [Revised: 10/31/2014] [Accepted: 11/03/2014] [Indexed: 12/24/2022]
Abstract
Nuclear receptors (NRs) are key players in the regulation of gene expression, coordinating protein assemblies upon their surfaces. NRs are regulated by ligand binding, which remodels the interaction surfaces and subsequently influences macromolecular complex formation. Structural biology has been instrumental in the discovery of some of these ligands, but there are still orphan NRs (ONRs) whose bona fide ligands have yet to be identified. Over the past decade, fundamental structural and functional breakthroughs have led to a deeper understanding of ONR actions and their multidomain organization. Here, we summarize the structural advances in ONRs with implications for the therapeutic treatment of diseases such as metabolic syndrome and cancer.
Collapse
Affiliation(s)
- Nerea Gallastegui
- The Institute of Biomedicine of the University of Barcelona (IBUB), Department of Biochemistry and Molecular Biology, University of Barcelona (UB), Baldiri Reixac 15-21, 08028 Barcelona, Spain
| | - Jonathan A G Mackinnon
- The Institute of Biomedicine of the University of Barcelona (IBUB), Department of Biochemistry and Molecular Biology, University of Barcelona (UB), Baldiri Reixac 15-21, 08028 Barcelona, Spain
| | - Robert J Fletterick
- The Department of Biochemistry and Biophysics, University of California San Francisco (UCSF), San Francisco, CA, USA
| | - Eva Estébanez-Perpiñá
- The Institute of Biomedicine of the University of Barcelona (IBUB), Department of Biochemistry and Molecular Biology, University of Barcelona (UB), Baldiri Reixac 15-21, 08028 Barcelona, Spain.
| |
Collapse
|